Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [5][4]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to a range of $1.840 billion to $1.854 billion from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations. The company also projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 to $73.89 [6].

Pro-Dex, Inc. ( PDEX ) manufactures surgical drivers and shavers, used mostly in orthopedic medical devices. I covered the name a few years ago, since when its situation has not changed meaningfully, in a consistent trendLong-only investment, evaluating companies from an operational, buy-and-hold perspective.Quipus Capital does not focus on market-driven dynamics and future price action. Instead, our articles focus on operational aspects, understanding the long-term earnings power of companies, the competit ...

Pro-Dex, Inc. ( PDEX ) manufactures surgical drivers and shavers, used mostly in orthopedic medical devices. I covered the name a few years ago, since when its situation has not changed meaningfully, in a consistent trendLong-only investment, evaluating companies from an operational, buy-and-hold perspective.Quipus Capital does not focus on market-driven dynamics and future price action. Instead, our articles focus on operational aspects, understanding the long-term earnings power of companies, the competit ...

Core Viewpoint - Resmed is set to release its financial and operational results for the second quarter of fiscal year 2026 on January 29, 2026, after market close, followed by a management webcast to discuss the results and other relevant information [1]. Company Overview - Resmed is dedicated to creating life-changing health technologies, focusing on innovative solutions that empower individuals in 140 countries to lead healthier lives [2]. - The company utilizes AI-powered digital health solutions, cloud-connected devices, and intelligent software to enhance home healthcare, making it more personalized and effective [2]. - Resmed envisions a future where everyone can achieve their full potential through improved sleep and breathing, with care provided in their own homes [2]. Earnings Webcast Details - The earnings webcast will take place on January 29, 2026, at 1:30 p.m. PST / 4:30 p.m. EST, with international times noted for London and Sydney [3]. - A replay of the webcast will be available on Resmed's investor relations website approximately two hours after the live event, with a phone replay accessible from January 29, 2026, until February 12, 2026 [2].

Core Insights - Treace Medical Concepts has successfully completed the first case using its new Lapiplasty Lightning™ technology, which aims to enhance the surgical treatment of bunions and related midfoot deformities [1] Company Overview - Treace Medical Concepts, Inc. is focused on advancing the standard of care for surgical management of bunions, which affect approximately 67 million Americans, with an estimated 1.1 million being annual surgical candidates [6] - The company has developed the patented Lapiplasty 3D Bunion Correction System, which addresses the root cause of bunions by correcting deformities in all three planes [6] Product Development - The Lapiplasty Lightning™ technology builds upon the existing Lapiplasty System, introducing advanced instrumentation that reduces surgical steps and improves precision in three-dimensional corrections [2][3] - The company plans to initiate a limited market release of the Lapiplasty Lightning™ System in mid-2026, with full commercialization expected by the end of the year [3] Surgeon Feedback - Dr. William T. DeCarbo, who performed the first case with the Lightning technology, noted that the instrumentation is intuitive and allows for faster procedures with greater accuracy and control [3]

SOUTH JORDAN, Utah, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that its Board of Directors unanimously appointed F. Ann Millner, Ed.D., formerly Merit’s Lead Independent Director, as Chair of the Board effective January 5, 2026. Dr. Millner has served as a director of Merit since 2015 and as the Lead Independent Director since July 2021. She previously served as the Chair of Merit’s Governance and Sustainability Com ...

IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its preliminary, unaudited topline financial results and key metrics for the quarter ended December 31, 2025. Members of the Company’s management team will host in-person meetings in San Francisco, CA from January 12, 2026 through January 14, 2026 to discuss preliminary topline fourth quarter 2025 financial results and key metri ...

GERMANTOWN, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable CGM systems for people with diabetes with Sequel MedTech, LLC, a company developing state-of-the-art insulin delivery technologies, have launched the integration of their products with the first patients having received a Sequel twiist AID system paired with the Eversense 365 CGM. The commercial lau ...

Core Insights - Dividend aristocrats often focus on well-known companies, but there exists a lesser-known tier that has consistently raised dividends for 30 to 50+ years [2] - Companies that can increase dividends annually for decades demonstrate strong business models capable of withstanding economic challenges [3] Company Highlights - **Abbott Laboratories**: - Raised dividends for 54 consecutive years with a current yield of 2.00% and an annual dividend of $2.52 [4] - The company has a 7.14% dividend growth rate and a 30.15% payout ratio, indicating strong cash flow management [4] - Operates in diverse sectors including diagnostics and medical devices, which mitigates single-market risks and supports long-term earnings growth [5] - **Hormel Foods**: - Achieved 60 consecutive years of dividend increases, yielding 5.07% with an annual dividend of $1.17 [8] - The company has a modest 2.20% dividend growth rate, but the high starting yield contributes to an attractive total return profile [8] - **Automatic Data Processing**: - Offers a 10% dividend growth rate supported by stable payroll revenue, which remains resilient during economic downturns [7]

Core Viewpoint - Teleflex Incorporated (TFX) experienced a significant decline in share price following leadership changes and a lowered revenue outlook for the year [1]. Group 1: Leadership Changes - Stuart Randle has been appointed as Interim President and Chief Executive Officer, effective immediately, succeeding Liam Kelly, who has stepped down from his roles as Chairman, President, and CEO [1]. Group 2: Stock Performance - Shares of Teleflex fell by 11.32 percent, dropping $14.32 to $112.21 from a previous close of $126.53 [1][2]. - The stock opened at $112.50 and traded within a range of $108.39 to $115.00 during the session on the New York Stock Exchange [2]. - Trading volume reached approximately 1.38 million shares, significantly higher than the average volume of about 0.64 million shares [3]. Group 3: Historical Context - Teleflex's shares have fluctuated within a 52-week range of $102.58 to $185.94 [3].